Peter Maag, Kyverna Therapeutics CEO

Kyver­na Ther­a­peu­tics files for IPO as au­toim­mune CAR-T space heats up

Kyver­na Ther­a­peu­tics, a clin­i­cal-stage biotech ex­am­in­ing CAR-T cell ther­a­py’s po­ten­tial to treat au­toim­mune dis­eases, has filed for an ini­tial pub­lic of­fer­ing.

The Cal­i­for­nia biotech plans to list as “KYTX” on the Nas­daq, per SEC pa­per­work filed Tues­day. End­points News re­port­ed Fri­day that Kyver­na was con­sid­er­ing go­ing pub­lic as ear­ly as Feb­ru­ary.

Kyver­na joins an IPO queue of at least five oth­er biotechs look­ing to go pub­lic this year. That in­cludes late-stage can­cer drug­mak­ers CG On­col­o­gy and Ar­riVent Bio­phar­ma, Phase II biotech Al­to Neu­ro­science, pre­clin­i­cal gene edit­ing com­pa­ny Metageno­mi and obe­si­ty gene ther­a­py mak­er Fractyl Health, which have all filed for list­ings in re­cent weeks.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.